Compare AstraZeneca plc (AZN) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Microsoft — how do they compare? AstraZeneca plc trades at $166.5 (market cap $253.13B), while Microsoft trades at $386.5 (market cap $2.86T). The key difference: Microsoft is far larger — about 11.3× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | MSFT | |
|---|---|---|
Market Cap | $253.13B | $2.86T |
Sector | Health | Technology |
52-Week High | $209.48 | $542.07 |
52-Week Low | $137.44 | $352.83 |
Enterprise Value | $279.37B | $2.84T |
Dividend Yield | 1.92% | 0.95% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $390.99, up 1.53% today, with a neutral technical signal and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust at $281.72B for 2025, supported by 68.31% gross margins and $136.16B in operating cash flow. Analyst consensus is overwhelmingly bullish with 80.49% buy ratings and a $552.81 price target, representing 41% upside potential from current levels.
Microsoft's AI leadership and cloud momentum position it for continued growth, though elevated capital expenditures and competitive pressures present near-term headwinds. The stock's current valuation at 23.29 P/E appears reasonable given the company's strong profitability and growth trajectory. Institutional ownership remains substantial, with recent news highlighting Azure's strength and Copilot adoption as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
